Scarica l'app Stockscreener
628.73
1.58%
9.78
Dopo l'orario di chiusura:
630.00
1.27
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$618.95
Aprire:
$628.07
Volume 24 ore:
974.34K
Relative Volume:
1.19
Capitalizzazione di mercato:
$65.92B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
15.32
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+1.16%
1M Prestazione:
-11.35%
6M Prestazione:
-13.02%
1 anno Prestazione:
+29.65%
Intervallo 1D:
$621.11
$633.88
Intervallo di 1 settimana:
$591.52
$633.88
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Alvotech targets J&J’s Simponi and Regeneron’s Eylea (ALVO) - Seeking Alpha
Cambridge biotech plans $450M IPO with Regeneron backing - The Business Journals
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
2026-06-04 | Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:REGN | Press Release - Stockhouse
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
CytomX expands collaboration with Regeneron - The Pharma Letter
Regeneron backed Parabilis seeks up to $476M in U.S. IPO - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold? - Yahoo! Finance Canada
Regeneron to present clinical data at diabetes and endocrine meetings - Investing.com
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets - BioSpace
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO - The Manila Times
Obesity and ultra-rare bone disease data from Regeneron at June conferences - Stock Titan
CytomX stock jumps on $37M Regeneron collaboration payment - Investing.com
Regeneron and CytomX extend cancer therapy partnership to $4bn deal - Pharmaceutical Technology
Strong Cash Yield: Is Regeneron Pharmaceuticals Stock A Buy? - Trefis
With Strong Cash Flow, Regeneron Pharmaceuticals Stock Poised to Rise? - Trefis
How Investors May Respond To Regeneron (REGN) EMA Fast-Track Review Of Otarmeni Gene Therapy - Yahoo Finance
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron - TipRanks
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
CytomX (NASDAQ: CTMX) adds programs, gains $37M from Regeneron - Stock Titan
Why Regeneron (REGN) Stock Is Trading Up Today - The Globe and Mail
CytomX Therapeutics (CTMX) Expands Collaboration with Regeneron Pharmaceuticals - GuruFocus
Regeneron rises 3.3% as investors focus on expanding oncology deal flow and bispecific R&D optionality - Quiver Quantitative
CytomX gains as licensing deal with Regeneron expands - MSN
CytomX expands Regeneron licensing deal (REGN:NASDAQ) - Seeking Alpha
CytomX stock jumps on $37M Regeneron collaboration payment By Investing.com - Investing.com Nigeria
CytomX expands Regeneron collaboration, receives $37M payment By Investing.com - Investing.com Canada
Inside CytomX’s new cancer alliance with Regeneron, worth up to $4B - Stock Titan
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
symbol__ Stock Quote Price and Forecast - CNN
Regeneron Shares Slump 25 Percent from Peak Despite Beating First Quarter Estimates - HarianBasis.co
Bronstein, Gewirtz & Grossman, LLC Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) And Encourages Shareholders to Connect - ACCESS Newswire
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Regeneron Pha - The National Law Review
Adult Myopia Market Emerging as a High-Growth Healthcare - openPR.com
Are Options Traders Betting on a Big Move in Regeneron Stock? - Yahoo Finance
Regeneron shares fall 12% since earnings despite strong Q1 beat - MSN
REGN Stock Price, Quote & Chart | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
Barclays initiates Regeneron stock with Overweight on Dupixent growth - Investing.com
Is Regeneron (REGN) Quietly Redefining Its Pipeline Focus With These Niche Therapy Advances? - simplywall.st
Regeneron develops Otarmeni, a surgically-delivered gene therapy drug - Lohud
(REGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
EMA Reviews Regeneron Gene Therapy Application For Hearing Loss - asatunews.co.id
Regeneron Pharmaceuticals shares dip amid rising selling pressure - Traders Union
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised) - The Globe and Mail
Is Regeneron Pharmaceuticals Stock Underperforming the Dow? - Yahoo Finance
Regeneron Pharmaceuticals Inc stock (US7739031091): shares steady as EMA accepts eye drug filing and - AD HOC NEWS
13,565 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Eurizon Capital SGR S.p.A. - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.58%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):